Phenylephrine IV bags recalled due to sterility validation gaps
Central Admixture Pharmacy Services has recalled 472 phenylephrine IV bags distributed nationwide due to insufficient validation data for sterilization processes.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Phenylephrine is administered intravenously, making it a risk-of-harm product. The recall is due to lack of sterility assurance from inadequate validation data. Although no illnesses or injuries have been reported, the potential for serious infection from a contaminated IV medication justifies a High severity rating.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling phenylephrine 50 mg in 0.9% sodium chloride 250 mL IV bags (NDC 72196-7039-1). The recall involves 472 bags distributed nationwide.
The recall is due to a lack of assurance of sterility. The manufacturer failed to provide adequate validation data for decontamination cycles, raising concerns about whether the sterilization processes were sufficient to ensure the product is free from contamination.
Affected lot numbers are 36-251703 (expiration 8/28/2023) and 36-251704 (expiration 8/29/2023). Healthcare providers who have received these products should immediately cease use and contact Central Admixture Pharmacy Services or the FDA with any information about the receipt or use of the recalled product.
The recalled product
- Product
- phenylephrine 50 mg added to 0.9% sodium chloride 250mL, CONCENTRATION = 200mcg/mL, IV Bag, Rx Only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Phoenix, AZ 85043. NDC:72196-7039-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Intravenous / Injectable
- Hazard
- lack-of-sterility
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot: 36-251703
- Exp. 8/28/2023
- 36-251704
- Exp. 8/29/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27